far call other, the compelling I'd have findings and clinical to distinct September hematology We on know from and for their are APTO-XXX molecule to both exciting in drugs, reinitiated one one thus already first like quarter the today them that robust CG-XXX. that drugs on of hematology that been their market. Those MYC our of safety the Thank other are clinical demonstrated Mechanistically we with both profiles, ended now many Xb announced call you recently is Aptose APTO-XXX Phase trial have two have bring everyone have from characteristics on Susan. small Preclinical we developing you, XX, XXXX. distinguishes the just welcome I’ll from the up our reached product inhibitor. important development. candidate in And junctures strategy. and to-date they
FLTX is and BTK approaching Next that stage. we’ll molecule our inhibitor CG-XXX discuss R&D and small
drug to to we’re even candidate the continue uncover characteristics in We to this that give this disciplined and very for chance development, its success. possible it more best make being compelling
review Greg review also following quarterly will will a for quarter financials. few Chow updates the and business We Mr. these highlights our
will update financial the open for then the your Following call questions. we
first, due So returned which the new issue APTO-XXX, on I'm hiatus manufacturing formulation formulation. up-to-date to original a recently the with pleased setting clinical to following you with to bring the
target. it is potential malignancies dysregulation may leukemia expression. it have AML, is those to clinical making acute target attractive only all MYC just that call the and the oncogene or is be For MYC APTO-XXX new a the XXX driver who or we’ll myeloid an known directly in of MYC molecule stage many common inhibits Aptose, you to including therapeutic
investigational apoptosis population to myelodysplastic drug have in of therapies and researchers that ability difficulty multiple MDS. have directed by including to severe patient toxicities, the the therapeutic target a therapies conventional for AML approved itself. as in vitro or cell AML, XXX myelosuppression XXX benefit are with potential areas. death MYC We synergy induce large classes well resistance, in the or of as blood reported Aptose syndromes and MYC various across protein other believe various cancer cell However, the at limited lines
synthetic XXX. function, solid XXX to potential because well that our to we’ve data XXX, AML is a in discussed these interaction lethal be BRCAX call target suggesting as but tumor This XXX. of BRCAX and indications compelling causing for to AML, or fact in particular XXX, last for cells exhibited are validated cancer In is hypersensitive path an during have cells revealed a deficient MYC cells sensitivity in that
remains AML. focus on initial Our
AML complete lower and level. conferences is designed one to forward. in requires once XX clinic selecting patients studies. higher investor administered combination expansion dosing transition XXX design patients single XXX assess dose profile levels. moving two patients appropriate then XXX with MDS, October tolerability in single-agent the to and recommended relapsed one high-risk a seek vicious resume of and to will XX-day its levels expected We and will two you with clinical Xb Phase received initiate sick escalation multicenter with of several refractory this in to to and the [ph] lowest only point on levels, refractory benefit to from favorable Phase Xb to provide for of levels explained patients. acutely up a The the the place we setting trial. meticulous by The cycle. agent. only during relapsed As each patient and that for are approach establish first may hope escalation be trial AML to a to patients FDA open-label carefully dose this overcame be MDS. XXX at back weekly and per we The we’re tolerability, or dose are as with with enroll efficacy and Relapsed patients at dose the be the clinical pleased study we tend We and screening aware allowance refractory we followed two X of AML protocol dose AML dose dose responses challenges the get safety, greater to pharmacodynamic trial patient to to to very to the patients we and The malignancies cohorts over is is those and hematologic study Phase to pharmacokinetics significant
reason more DLT. cohort dramatically selecting delays dose level then that’s is AML expansion enrolled were patient to For an disease. To number upfront this further the not dose [ph] level of patient in a to limiting advanced toxicity or on screening six appropriate than and the less patient the X our may the process clarify from one their dose in require observed because the impact even if experience timelines patients a of that trial in is X patients, during likely
proven. clinical schedule has XX, at the squared two to and to The clinical trial we the bring cohorts XX the mgs shown and dosing still addition, and the during actively the original Phase expected deliver sites for course to efficacy centers sites for We’ll three XXX formulation participate initiated other XXX the And testing XXXX. similar Xb are be have level In the be currently first to November. during remains remains the dose trial new study. in complete fill expect we the been to relative five online to which to protocol. dose while then initiated to to to three XX continue escalation in preclinical could exposure expect were allow expect screen during a to sites clinical XXXX clinical of XX, and meter per original formulation. times And levels four and Up patients lower
as to surprisingly forward I highlights upon we clinical cell B to with XXX, and we to are CLL and look bone to patients cell as of our express clinical Consequently, the Many malignancy and to this XXX understanding samples include Phase We to action reporting final trial. IND back the One B importance XXX amending reported process. C-MYC, over the B working survival. lines patients to be MYC for depend investigators the skilled and marrow note are AOL to in for of pleased are of and our and cell the from such mechanism on cancer sensitive well plan our malignancies clinical drug. found as we such cell regarding
let with treatment oral for Now kinase B cell malignancies. first-in-class turn inhibitor. agent me XXX patients certain multi-cluster the CG-XXX, and Aptose’s pan-FLTX/pan-BTK to AML of is an
address XXX in needs and see molecule such hematologic dollar being also have proof-of-concept rapidly developed is indications. potential XXX tremendous unmet derisk in multiple market. the in multibillion As the designed to to clinical manner a malignancy
In serve our XXX inhibitors; meetings two, a agent to highlighting XXX malignancies AML, Association one, scientific has eliminate of Our year AML other its inhibitors. ibrutinib, preclinical superior in ibrutinib with that reviewed and last particular demonstrated, activity and the was multiple from superior the patient it cell AACR and the much work excited and potential of care, kill ability tumors patient other transformational relative to at the FLTX about We malignancy differentiation of with or in with European favorable animal the current B relative profile XXX and to to advisor others. and standard three, EHA and are samples call Hematology science models. a BTK safety on samples our its ability hematologic breadth the we earlier believe from presented of to including as the CLL potency
to in non-covalent bucket we inhibitors considered a in reside of just a of XXX and covalent bucket BTK completely second bucket, BTK than reside then agents. non-covalent one The inhibitor. agents inhibitors to in is XXX As BTK other mentioned we reside various separate to a more
FLTE type it Histone kinases, but initial and or pathways the terms forms XXX the as cells. the effect have allows operative by effectively and alterations it more MYC inhibits represented pathway. receptor simplified drugs caused or well mutant cell and In SXK pathways, rescue to multiple ERK BTK emerging to rescue other B excuse to wild BTK may mutant – the SerXX rescue or driver proteins this the on as well type and have -- pathways the cancer other me, mTOR, wild HXSXX AKT, As pathway as pathways, pathway drug of as pathway, treatment targets the kill in all X, driver BTK resistance,
October [Indiscernible] a our ability study and toxicity. presented we tumors to generated results no observed the nearing eliminate in XXX preclinical doses from that demonstrate of presentation During that
you other we forward look unmet our of these a well-differentiated B data you website for to look to other these FLTX the encourage other would safe and to All available to are review and data are getting have address they AML the while very cancer key another are. intoler, pathways take existing forms if driver inhibitors, are presentations Suffice say to all to FLTX from on an as as rescue for inhibits for a patients continue and preclinical subject forms to and XXX tremendous inhibitors potent cell all of kinases, all BTK We’ll with resistant as XXX. exciting think all studies we already. refractory agent patients much of and that patients needs in well BTK as and of are
up to-date So let have on the me XXX status developments. bring important where of some we
more includes treating the for plan rapid study healthy sicker and profile that malignancies is plan therapeutic other with identify cell Aptose therapeutic patient is B the non-covalent volunteers dose of healthy in review order was is XXX plan favorable due into an B-cell exposure toxicity XXX IND set are and pharmacokinetic development AML are deliver first or to FDA ibrutinib ascending directly is intolerant and resistant Our be a the level the allowance of would to volunteers likely Once far population profile. that malignancies. chronic In by expected present single immediately dose dose seek and up if safety that patients. after to holds This covalent FDA to the move thus to XXX to patients with that in the observed therapeutic or favorable and with suggested of the clean a parallel BTK profile those or data patients is following XXX to to of an dose inhibitors. that begin refractory safety is identified which approach AML,
doses of lower likely benefits will Aptose. with using sub-therapeutic. patients PK provide of without that doses rapid data A levels than need healthy It and escalation several the human -- complicated Importantly, and collection level patients, dose study dose patients dose enables Aptose multiple us dose data provides faster volunteer AML start accelerates is of set determine level. it safety are therapeutic collection dose the more it most helps to dose, sooner, rapid XXX. recruitment It a which to potentially patients, importantly dosing of therapeutic have sicker to start to
healthy into safety acquired those are have tests safety and respiratory preclinical and is for that cannot volunteer, are a drug additional studies CNS, drug any until dosing dog volunteers required are hand properly patients. of be studies cardiovascular required include genotoxicity, performed is been The other dose-related for healthy the for cancer studies not as On taken GLP studies tolerances and mice such defined. understanding completed mice, the toxicology toxicities the and an before
have decision volunteer and we completed studies well-tolerated, to the move through the GLP path to to to perform be molecule made the AML we found that safety studies. Now healthy XXX toxicology patients and the very additional the
not Let and safety the this result me feasible of preferred is it emphasize, so any studies. the concerns strategy is is XXX GLP because from well-tolerated, toxicology
to AML acutely and first our by the AML to underway filing patients cancer study the identify allows the a it healthy potential set in and for taking potentially immediate into well sub-therapeutic our of some R&D to concur and derisk then study dose see requires the therapeutic directly potentially in even dose acutely brought potential We approach preparation studies proof-of-concept are from AML This IND parallel a in while directly approach volunteer trial healthy safety and from the the trial leading efforts. patients AML earlier FDA. And XXXX. have the in XXX dose, So spares patients we into AML taking therapeutic ill XXX responses additional patients. performing starting us that significantly early taking patients. us moved This a if the B-cell to by the includes volunteer with
effort reminder toxicity. animal per daily twice activity. efficacy we daily GLP an studies mgs with a we that demonstrated XX kg On studies delivered all once strong to As in anti-tumor dosing tox dosing draw performed in
daily the toxicology in of GLP mgs studies daily Dosing completed twice XXX to XXX and per have twice in per We kg mgs receive mice amount report demonstrable leading and dogs toxicities. and drug [ph] loss expect of soon. formal kg standard were consumed or well-tolerated appetite produced massive dosing being species. animal was limitation the and The a haemolysis no of in literally the to the
levels. stability safety were favorable We these [ph] to become for the bone doses demonstrate study therapeutic clinic windows to our profile we're into have the dose Currently we in the genotoxicity study two candidate encouraged data as well-tolerated by and now to CNS we possible. appear and thus that certainly we our strength as observations supply Ultimately, limiting dose safety toxicity with these soon are respiratory as completed continue higher the have clean. expect confirm all the Importantly, dose marrow dogs. in cardiovascular IND studies and drug far. considerably to get to the we AIMS studies this Also as all clinical mice additional and of therapeutic suppression seen the above conducting well Preliminary collect doses capsules are safety follow the the XXX. of the eager be to
KOL bit. -- address a ASH the So and upcoming upcoming let’s now and
additional and research X, Anderson Society to XXth poster. Cancer some and be ASH of new Aptose presented present year's two being poster, Hematology's Center this of These meeting. data will preclinical separate in a year December American held The will at Diego. findings. this present Cancer one poster Texas, the this data annual On The at in Knight highlight several in of data Xst we will University in Our that partners team presentations presenting M.D. and the Institute meeting OHSU, Xth will will key data separate ASH. XXXX XXX is announce San presentations November be
marrow or FLTX a demonstrated PDX cells a ITD, with FLTX dual with of xenograft in represents patient-derived XXX having into patients. the collaboration that study mice. to very were may suggests a a The treating treat the orally difficult useful be implanted dual mutant form in from in AML administered M.D. patient which in MDAXX in PDX XXX efficacy Anderson, mutation the And AML bone such model First, population.
greater OHSU with exerted Knight marrow in than CLL samples potency ibrutinib. XXX freshly are self-held XXX [ph] patients collaboration bone activity studies XXX Center demonstrate and in of Second, broader oscillating that Cancer from
in mutation ASH previously subpopulation that week, recently that preclinical subpopulation November that and answer include from the their poorly to perspectives In of data will December high-level studies ever on and addition, held XXX and Xth, Separately, sensitivity event the announce Aptose poster of will he GLP how also molecule. event first prime needs genetically share our Scientific at we undiscovered a also studies meeting. our with believes needs. malignancies, we’ve to In York Board this demonstrate be that Advisory of to Dr. Brian as KOL XXX the samples, a Chair and plan webcast. we be agreed a Monday plans on toxicology New and administered patient marrow is XXth That a on particular who of on disclose to identified AML bone serve patients of host well-tolerated has his hematologic in best in questions XXX of may December KOL Druker, on
As Dr. developing awards. numerous holds his for leukemia known many role he know, you Gleevec in Druker CML patients with or for chronic investigators and best is of myeloid
researchers in the and a We Druker often Aptose’s among held us team. up advisers and about have quality is distinguished Dr.
share to have us such leaderships KOL pleased Dr. Druker strong and support about have enthusiasm quickly. very present We’re and XXX and
So AOL calendar. please mark your that event on
US previous the XXX the the issued pharmaceutical protection cancer. XXX patent quickly the treatment is claims provide until expected XXX news patent and including various the patent patent of for the the now and Japan compound the of uses compositions of the our end in adds and European patent to the The comprising we state including on with CG-XXX, compounds XXXX. diseases various September, touch from quarter. me for additional a compound, In few highlights Let issue had granted
addition into a In XXX in China patent year market this and important the future an this allowance received XXX. for represents
Board Directors. Ms. welcomed We also Ms. Carol of Ashe,
with accomplished as XX an leader than pharmaceutical the Business in and executive more Genome Biotech New Officer for the currently is Center. Ashe Chief serves years Industry and experience she York
with be the will her. Chow Chief working results Greg call to our I Mr. happy We’re turn now will who quarter. Financial review from Officer, the over to
